|
Status |
Public on May 12, 2020 |
Title |
T47D_WT_basal_batch1_3 |
Sample type |
RNA |
|
|
Source name |
Cell line
|
Organism |
Homo sapiens |
Characteristics |
cell line: T47D growth protocol: T47D growing under E2 maintenance timepoint: basal batch: batch1-Y2014Dec description: replicate 3
|
Extracted molecule |
total RNA |
Extraction protocol |
mRNA were extracted with RNeasy Mini Kit (Qiagen), as per the manufacturer's instructions, and quantification performed using the Agilent 2100 Bioanalyzer (Santa Clara, CA, USA).
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
|
|
Hybridization protocol |
Standard Illumina hybridization protocol
|
Scan protocol |
Standard Illumina scanning protocol of iScan
|
Description |
T47D.basal.3
|
Data processing |
The data were divided into subsets according to the groups being compared; only the samples involved in a given comparison are used. Subsets were then filtered to remove any non-expressed probes using the detection p-value from Illumina. Across all samples in each subset probes for which the intensity values were not significantly different (p>0.01) from the negative controls were removed from the analysis. Following filtering the data was transformed and normalized using variance-stabilizing transformation (VST) and robust spline normalization (RSN) method in the lumi package in R. The RSN combines the features of quantile and loess normalization.
|
|
|
Submission date |
May 16, 2017 |
Last update date |
May 12, 2020 |
Contact name |
Alice Gao |
E-mail(s) |
alice.gao@icr.ac.uk
|
Organization name |
The Institute of Cancer Research
|
Department |
Breast Cancer Now
|
Lab |
Molecular Cell Biology
|
Street address |
237 Fulham Road
|
City |
London |
State/province |
London |
ZIP/Postal code |
SW3 6JB |
Country |
United Kingdom |
|
|
Platform ID |
GPL10558 |
Series (2) |
GSE98987 |
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome [Illumina] |
GSE99003 |
Resistance to Palbociclib involves multiple mechanisms amenable to targeting with drug holidays or drug switching to improve therapeutic outcome |
|